Clinical trial
Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or…
NCT00375193 · Celgene, Industry · Completed
Key facts
| NCT number | NCT00375193 |
|---|---|
| Title | Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy |
| Official title | A Phase 2 Trial of Single-Agent Amrubicin in Patients With Extensive Disease Small Cell Lung Cancer That is Refractory or Progressive Within 90 Days of Completion of First Line Platinum-based Chemotherapy |
| Lead sponsor | Celgene, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Amrubicin |
| Enrollment | 75 |
| Start date | Nov 1, 2006 |
| Primary completion | May 1, 2008 |
| Completion | Mar 1, 2009 |
| First posted | Sep 12, 2006 |
| Last update posted | Oct 24, 2019 |
| Countries | Netherlands, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: